CryoLife takes haemostatic tech to Canada with Sorin
This article was originally published in Clinica
Biomaterials and tissue processing company CryoLife is set to make its Hemostase MPH bleeding control agent available in Canada through the Canadian subsidiary of cardiovascular firm Sorin. Hemostase uses microporous polysaccharide hemospheres technology (MPH), which CryoLife says produces a plant-based powder that rapidly dehydrates blood and enhances clotting. According to the firm, pre-clinical trials show that Hemostase “does not promote infection and absorbs with 24-48 hours of application at the wound site, compared to other surgical haemostats which can take 3-8 weeks or more to fully break down”. CryoLife (Atlanta, Georgia) began distributing Hemostase in the US, UK and Germany in the second quarter of 2008 and expects to expand into other geographical markets this year and the next. Financial details of the deal with Sorin were not disclosed.